Introduction: A recent clinical trial underscored the importance of repeated minimal residual disease (MRD) monitoring by RQ-PCR in Mantle Cell Lymphoma (MCL), a disease with initially high response rates but both early and late relapses [Ferrero Blood 2022]. However, MRD kinetics are complex, posing interpretation and clinical application challenges.
Unraveling MRD Dynamics to Enhance Outcome Prediction in Mantle Cell Lymphoma—Insights from the Fondazione Italiana Linfomi MCL0208 Clinical Trial / Cordero, F., Ferrero, S., Pernice, S., Genuardi, E., Volpatto, D., Sirovich, R., Civita, A.M., Evangelista, A., Ragaini, S., Di Rocco, A., Re, A., Stefanoni, V., Cavallo, F., Boccomini, C., Balzarotti, M., Zilioli, V.R., Gomes Da Silva, M., Arcaini, L., Tosi, P., Zaccaria, G.M., et al.. - In: HEMATOLOGICAL ONCOLOGY. - ISSN 0278-0232. - STAMPA. - 43:S3(2025). [10.1002/hon.70096_532]
Unraveling MRD Dynamics to Enhance Outcome Prediction in Mantle Cell Lymphoma—Insights from the Fondazione Italiana Linfomi MCL0208 Clinical Trial
Zaccaria, G. M.;
2025
Abstract
Introduction: A recent clinical trial underscored the importance of repeated minimal residual disease (MRD) monitoring by RQ-PCR in Mantle Cell Lymphoma (MCL), a disease with initially high response rates but both early and late relapses [Ferrero Blood 2022]. However, MRD kinetics are complex, posing interpretation and clinical application challenges.| File | Dimensione | Formato | |
|---|---|---|---|
|
2025_Unraveling_MRD_Dynamics_to_Enhance_Outcome_Prediction_in_Mantle_Cell_Lymphoma—Insights_pdfeditoriale.pdf
solo gestori catalogo
Tipologia:
Versione editoriale
Licenza:
Tutti i diritti riservati
Dimensione
453.86 kB
Formato
Adobe PDF
|
453.86 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
